首页> 外文期刊>Clinical and experimental allergy : >Priorities for future research into asthma diagnostic tools: A PAN PAN ‐ EU EU consensus exercise from the European asthma research innovation partnership ( EARIP EARIP )
【24h】

Priorities for future research into asthma diagnostic tools: A PAN PAN ‐ EU EU consensus exercise from the European asthma research innovation partnership ( EARIP EARIP )

机译:未来研究哮喘诊断工具的优先事项:Pan Pan - 欧盟欧盟欧洲哮喘研究创新伙伴关系的共识运动(蜈蚣耳机)

获取原文
获取原文并翻译 | 示例
           

摘要

Summary The diagnosis of asthma is currently based on clinical history, physical examination and lung function, and to date, there are no accurate objective tests either to confirm the diagnosis or to discriminate between different types of asthma. This consensus exercise reviews the state of the art in asthma diagnosis to identify opportunities for future investment based on the likelihood of their successful development, potential for widespread adoption and their perceived impact on asthma patients. Using a two‐stage e‐Delphi process and a summarizing workshop, a group of European asthma experts including health professionals, researchers, people with asthma and industry representatives ranked the potential impact of research investment in each technique or tool for asthma diagnosis and monitoring. After a systematic review of the literature, 21 statements were extracted and were subject of the two‐stage Delphi process. Eleven statements were scored 3 or more and were further discussed and ranked in a face‐to‐face workshop. The three most important diagnostic/predictive tools ranked were as follows: “New biological markers of asthma (eg genomics, proteomics and metabolomics) as a tool for diagnosis and/or monitoring,” “Prediction of future asthma in preschool children with reasonable accuracy” and “Tools to measure volatile organic compounds ( VOC s) in exhaled breath.”
机译:None

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号